跳至主要内容
临床试验/JPRN-jRCT1051210196
JPRN-jRCT1051210196招募中未知

A Multicenter Randomized Controlled Study of the Efficacy and Safety of Daprodustat in Heart Failure Patients with Renal Anemia

Minamino Tohru0 个研究点目标入组 50 人开始时间: 2022年3月18日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 90age old(—)
性别
All

入选标准

  • Patients meet all of the following selection criteria and do not meet any of the exclusion criteria,will be eligible for the study.
  • 1)Patients with heart failure who are 20 to 90 years old at the time of obtaining consent
  • 2)eGFR<60mL/min/1.73m^2 at screening
  • 3)Patients without atrial fibrillation at screening:BNP >100 pg/mL or NT-proBNP >600 pg/mL
  • Patients with atrial fibrillation at screening: BNP >150 pg/mL or NT-proBNP >900 pg/mL
  • 4)Hemoglobin level >=7.5 g/dL and <11 g/dL at screening
  • 5)Ferritin level>=100 ng/mL and TSAT>=20% at screening
  • 6)Folic acid and vitamin B12levels must be above the lower limit of normal at screening.
  • 7)Patients who have received sufficient explanations for participating in this study and have given their free written consent with full understanding.

排除标准

  • 1) NYHA class III/IV
  • 2) On hemodialysis or peritoneal dialysis, or scheduled to be on hemodialysis in the next 6 months at informed concent
  • 3) Treated with an ESA within 5 weeks prior to enrollment
  • 4) Erythrocyte transfusion within 12 weeks prior to enrollment or expected to occur during the study period
  • 5) Patients who have been treated with HIF-PH inhibitor
  • 6) Patients with anemia other than chronic kidney disease and current or recent bleeding
  • 7) History of sickle cell disease, myelodysplastic syndrome, myelofibrosis, hematologic tumor, myeloma, hemolytic anemia, thalassemia, or locus coeruleus
  • 8) History of pulmonary hypertension, polycystic kidney disease
  • 9) Malignancy noted within 2 years, except for treated basal cell carcinoma of the skin, squamous cell carcinoma cured by resection, or cervical intraepithelial carcinoma
  • 10) History of acute myocardial infarction, cerebral infarction, deep vein thrombosis, or pulmonary thromboembolism within 48 weeks prior to enrollment
  • 11) Others who are judged by the principal investigator to be inappropriate as research subjects

研究者

发起方
Minamino Tohru

相似试验